SYDNEY, Australia and MINNEAPOLIS, Oct. 08, 2017 (GLOBE NEWSWIRE) — Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, is pleased to announce it has entered into an agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka).